Front. Neurosci. Frontiers in Neuroscience Front. Neurosci. 1662-453X Frontiers Media S.A. 10.3389/fnins.2021.743596 Neuroscience Correction Corrigendum: Top-Down Proteomics of Human Saliva Highlights Anti-inflammatory, Antioxidant, and Antimicrobial Defense Responses in Alzheimer Disease Contini Cristina 1 † Olianas Alessandra 1 † Serrao Simone 1 Deriu Carla 1 Iavarone Federica 2 3 Boroumand Mozhgan 4 Bizzarro Alessandra 5 Lauria Alessandra 5 Faa Gavino 6 Castagnola Massimo 4 Messana Irene 7 Manconi Barbara 1 * ‡ Masullo Carlo 8 ‡ Cabras Tiziana 1 ‡ 1Dipartimento di Scienze della Vita e dell'Ambiente, Università di Cagliari, Cagliari, Italy 2Dipartimento di Scienze Biotecnologiche di Base, Cliniche Intensivologiche e Perioperatorie, Università Cattolica del Sacro Cuore, Rome, Italy 3Fondazione Policlinico Universitario “A. Gemelli” – IRCCS, Rome, Italy 4Laboratorio di Proteomica, Centro Europeo di Ricerca sul Cervello, IRCCS Fondazione Santa Lucia, Rome, Italy 5UOC Continuità Assistenziale, Fondazione Policlinico Universitario “A. Gemelli” – IRCCS, Rome, Italy 6Dipartimento di Scienze Mediche e Sanità Pubblica, University of Cagliari, Cagliari, Italy 7Istituto di Scienze e Tecnologie Chimiche “Giulio Natta”, Consiglio Nazionale delle Ricerche, Rome, Italy 8Dipartimento di Neuroscienze, Sez. Neurologia, Università Cattolica del Sacro Cuore, Rome, Italy

Edited and reviewed by: Rossen Donev, MicroPharm Ltd, United Kingdom

 *Correspondence: Barbara Manconi bmanconi@unica.it

This article was submitted to Neurogenomics, a section of the journal Frontiers in Neuroscience

†These authors have contributed equally to this work and share first authorship

‡These authors have contributed equally to this work and share last authorship

 13 08 2021 2021 15 743596 18 07 2021 22 07 2021 Copyright © 2021 Contini, Olianas, Serrao, Deriu, Iavarone, Boroumand, Bizzarro, Lauria, Faa, Castagnola, Messana, Manconi, Masullo and Cabras. 2021 Contini, Olianas, Serrao, Deriu, Iavarone, Boroumand, Bizzarro, Lauria, Faa, Castagnola, Messana, Manconi, Masullo and Cabras

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

 A Corrigendum on Top-Down Proteomics of Human Saliva Highlights Anti-inflammatory, Antioxidant, and Antimicrobial Defense Responses in Alzheimer Disease by Contini, C., Olianas, A., Serrao, S., Deriu, C., Iavarone, F., Boroumand, M., et al. (2021). Front. Neurosci. 15:668852. doi: 10.3389/fnins.2021.668852 Alzheimer disease salivary proteomics S100A cystatins α-defensins thymosin β4 antimicrobial peptides oxidative stress

In the original article, the Supplementary Table 4 and the Supplementary Figure 6, cited on page 6 in the original article, are missing from the Supplementary Materials. The corrected Supplementary Table 4 and Supplementary Figure 6 are shown below. The Supplementary Material of the original article has been updated.

XIC peak areas values (mean ± SD) normalized on TPC, frequencies and p-values obtained by statistical analysis by comparing the three patients' groups treated with different therapies by non-parametric ANOVA with the Krustal-Wallis test and Dunn's post test. p-values > 0.05 are not statistically significant (∙).

Peptide XIC Peak Areas x 105(mean ± SD) and Frequency
G1 (nr 19) G2 (nr 8) G3 (nr 8) HC (nr 34) ANOVA p value
α-defensin 1 2.2 ± 2.3 (19) 2.3 ± 1.8 (8) 0.6 ± 0.8 (5) 0.5 ± 0.6 (24) p <0.0001 (G1vs G3*, G2 vs G3*, G1 vs HC***, G2 vs HC**)
α-defensin 2 1.5 ± 1.5 (19) 1.5 ± 1.2 (7) 0.4 ± 0.6 (5) 0.4 ± 0.4 (27) p = 0.0003 (G1vs G3*, G1 vs HC**, G2 vs HC*)
α-defensin 3 0.7 ± 0.5 (16) 0.8 ± 0.5 (8) 0.2 ± 0.4 (2) 0.2 ± 0.3 (17) p <0.0001 (G1vs G3*, G2 vs G3*, G1 vs HC***, G2 vs HC**)
α-defensin 4 0.2 ± 0.3 (8) 0.4 ± 0.2 (8) 0.04 ± 0.08 (2) 0.05 ± 0.1 (11) p = 0.0004 (G1vs G2*, G2 vs G3**, G2 vs HC***)
Tβ4 0.5 ± 0.6 (14) 1.1 ± 0.9 (8) 0.2 ± 0.4 (3) 0.2 ± 0.4 (16) p = 0.002 (G2vs G3**, G2 vs HC**)
Stath. 2P 8.8 ± 7.7 (19) 5.9 ± 4.4 (6) 11.0 ± 7.1 (8) 1.1 ± 0.9 (33) p <0.0001 (G1 vs HC***, G2vs HC*, G3 vs HC***)
Stath. Des1-9 0.5 ± 0.6 (16) 0.6 ± 0.9 (6) 0.8 ± 0.6 (7) 0.08 ± 0.1 (24) p = 0.0002 (G1 vs HC**, G3 vs HC**)
P-C peptide 9.3 ± 5.1 (19) 8.6 ± 12.6 (6) 12.3 ± 6.9 (8) 5.6 ± 4.4 (34) p = 0.01 (G3 vs HC*)
Cyst. B tot 2.0 ± 2.2 (18) 1.9 ± 1.6 (8) 0.9 ± 1.2 (7) 9.3 ± 5.1 (27) p = 0.006 (G1vs HC*, G2 vs HC*)
Cyst A 1.8 ± 1.6 (17) 2.9 ± 1.9 (8) 1.2 ± 0.9 (7) 1.0 ± 0.9 (29) p = 0.02 (G2 vs HC*)
S100A8 tot 1.1 ± 1.5 (12) 0.9 ± 1.1 (6) 0.4 ± 0.5 (4) 0.08 ± 0.2(5) p <0.0001 (G1 vs HC***, G2 vs HC**)
S100A8-SNO 1.1 ± 2.3 (9) 0.7 ± 1.0 (3) Not detected Not detected p <0.0001 (G1 vs G3*, G1 vs HC***)
S100A9(S) tot 1.1 ± 1.5 (18) 0.9 ± 1.1 (7) 0.4 ± 0.5 (7) 0. .5 ± 0.8 (16) p <0.0001 (G1 vs HC***, G2 vs HC*)

Total protein concentration measured in the subgroups of patients with different pharmacological treatment.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher's Note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.